Taxol with avastin produces notewort...( INDIANAPOLIS The positive results o...),Health
INDIANAPOLIS The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.
The study with Avastin showed the biggest improvement in metastatic breast cancer ever reported in a chemotherapy-based clinical trial. It nearly doubled the time between initiation of chemotherapy for metastatic disease and progression of the breast cancer tumors.
The study was coordinated by the Eastern Cooperative Oncology Group (ECOG) and Kathy Miller, M.D., associate professor of medicine and Sheila D. Ward Scholar at the Indiana University School of Medicine, is the lead author.
Dr. Miller said she found the results exciting because this was the first study to show that an antiangiogenic agent can delay progression of advanced breast cancer. The study looked at Taxol (paclitaxel), which is one of the standard agents for metastatic disease, with and without the addition of Avastin (bevacizumab).
This study not only achieved the longest progression-free survival in advanced disease but the therapy achieved that improvement without adding to the day-to-day treatment burden and with only minor increases in toxicity, said Dr. Miller.
The study enrolled 722 women with metastatic disease from the United States, Canada, Peru and South Africa. Patients were randomized to one of two arms of the phase III study Taxol alone or Taxol with Avastin. The patients, who joined the study from December 2001 through May 2004, represented a balance of age, disease-free interval, estrogen-positive receptors and sites of disease.
The results show that treatment with Taxol and Avastin increased the period patients went without progression of their disease from 5.9 months to 11.8 months.
The next step is to move Avastin into the initial treatment of breast cancer in hopes that it will prevent
'/>"/>
| Contact: Mary Hardin mhardin@iupui.edu 317-274-7722 Indiana University Source:Eurekalert |
Related medicine news :
1. Taxol bristle ball: a wrench in the works for cancer
2. Taxol-type drugs give slight boost to survival rates in early breast cancer
3. FDA Panel Says No to Avastin for Advanced Breast Cancer
4. Stem cell research produces a key discovery for Fragile X Syndrome
5. Haemacure Reports Third Quarter 2007 Results
6. Brooke Franchise Corporation Announces Selected July Results
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
11. Martek Announces Third Quarter 2007 Financial Results
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |